Skip to main content

Table 2 Population of the area of residence and the presence of CADM or anti-MDA-5 antibodies

From: Epidemiologic study of clinically amyopathic dermatomyositis and anti-melanoma differentiation-associated gene 5 antibodies in central Japan

    CADM α-MDA-5-positive
Population of area of residence (×1,000) Total number of DM patients (M:F) Mean age at onset (range) Number (%) of patients (M:F) Pvalue* Mean age at onset (range) Number (%) of patients (M:F) Pvalue** Mean age at onset (range)
T1 (0.5 to 108) 31 (4:27) 49.0 (4 to 70) 16 (51.6%) (1:15) P for difference = 0.096 47.3 (4 to 69) 14 (45.2%) (1:13) P for difference = 0.012 48.8 (20 to 66)
T2 (130 to 826) 26 (7:19) 44.0 (9 to 80) 10 (38.5%) (3:7) P for trend = 0.031 40.0 (9 to 59) 7 (26.9%) (3:4) P for trend = 0.003 39.9 (11 to 59)
T3 (2,200) 38 (17:21) 47.3 (1 to 79) 10 (26.3%) (4:6)   45.9 (1 to 73) 5 (13.2%) (1:4)   51.0 (39 to 63)
  1. CADM, clinically amyopathic dermatomyositis; DM, dermatomyositis; M:F, male:female; MDA-5, melanoma differentiation-associated gene 5. *Prevalence of CADM in total DM. **Prevalence of anti-MDA-5 in total DM.